{"id":4463,"date":"2025-09-09T18:11:34","date_gmt":"2025-09-09T15:11:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4463"},"modified":"2025-09-09T18:11:35","modified_gmt":"2025-09-09T15:11:35","slug":"belief-biomed-announced-successful-completion-of-first-dose-of-bbm-d101-gene-therapy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/belief-biomed-announced-successful-completion-of-first-dose-of-bbm-d101-gene-therapy\/","title":{"rendered":"Belief BioMed anunci\u00f3 la finalizaci\u00f3n exitosa de la primera dosis de la terapia g\u00e9nica BBM-D101"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Belief BioMed, una innovadora empresa de biotecnolog\u00eda centrada en el desarrollo de terapias gen\u00e9ticas de vanguardia, anunci\u00f3 hoy que el ensayo cl\u00ednico de registro (CTR20252461) de su inyecci\u00f3n BBM-D101 desarrollada y producida independientemente para la distrofia muscular de Duchenne (DMD) ha completado con \u00e9xito la primera dosificaci\u00f3n de pacientes en Beijing, China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La inyecci\u00f3n de BBM-D101, una terapia g\u00e9nica basada en AAV, utiliza una c\u00e1pside modificada para actuar eficazmente sobre el tejido muscular. Administrada en dosis m\u00e1s bajas que las de sus hom\u00f3logos extranjeros, se espera que ofrezca una seguridad favorable. La IND para BBM-D101 fue aprobada tanto por la Administraci\u00f3n Nacional de Productos M\u00e9dicos (NMPA) de China como por la Administraci\u00f3n de Alimentos y Medicamentos (FDA) de Estados Unidos en 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e1s informaci\u00f3n<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/es\/belief-biomed-bbm-d101-gene-therapy-phase-1-2-clinical-trial-nct07058662\/\" target=\"_blank\" rel=\"noreferrer noopener\">Comienza el ensayo cl\u00ednico de fase 1\/2 de la terapia g\u00e9nica BBM-D101<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Belief BioMed, an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the registration clinical trial (CTR20252461) of its independently developed and produced BBM-D101 injection for Duchenne Muscular Dystrophy (DMD) has successfully completed the first patient dosing in Beijing, China. BBM-D101 injection, an AAV-based gene therapy, utilizes an engineered capsid to efficiently [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4464,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[199,197,123,137,242,61],"class_list":["post-4463","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-bbm-d101","tag-belief-biomed","tag-china","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4463"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4464"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4463"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}